No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).

Monoclonal antibodies (mAbs) have been a key therapeutic option for non-communicable diseases for decades, and a small number of mAbs have helped treat infectious diseases, including COVID-19.

The rise of antibody therapeutics is transforming drug discovery, providing highly specific treatments for complex diseases ...

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can ...

Lyophilization plays a crucial role in successful biologic molecule development, but what is lyophilization – and how can it ...

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion. In 2021, five out of the top 10 selling drugs were ...

Advances in clinical development keep the hope alive of having new drugs in the not-so-distant future to complement the ...

Most discontinued anti-tau antibodies (red) targeted tau’s N-terminus. Of the antibodies currently in trials (green), bepranemab and E2814 presented results at CTAD, while JJ-63733657/posdinemab and ...

The Globe and Mail spoke with eight people whose pet’s health declined after taking Librela. Drugmaker Zoetis has responded ...

Certolizumab pegol is the fourth monoclonal antibody drug to be approved for the treatment of Crohn's disease, and the third in its class of TNF-α inhibitors. Importantly, the efficacy and safety ...

Centessa had recently conducted an interim analysis of a phase 2 study of its drug, called SerpinPC, which is designed to ...